80 related articles for article (PubMed ID: 1340689)
1. [Bone risk of hormone-suppressing therapy in differentiated thyroid epithelioma. Study by dual photon absorptiometry].
Leprat F; Austyn C; Commenges-Ducos M; Commenges D; Cochet C; Basse-Catalinat B; Ducassou D; Latapie JL
Ann Endocrinol (Paris); 1992; 53(5-6):224-9. PubMed ID: 1340689
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
[TBL] [Abstract][Full Text] [Related]
3. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
Sijanovic S; Karner I
Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
[TBL] [Abstract][Full Text] [Related]
4. The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma.
Kim MK; Yun KJ; Kim MH; Lim DJ; Kwon HS; Song KH; Kang MI; Baek KH
Bone; 2015 Feb; 71():101-5. PubMed ID: 25445448
[TBL] [Abstract][Full Text] [Related]
5. The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women.
Sajjinanont T; Rajchadara S; Sriassawaamorn N; Panichkul S
J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S71-6. PubMed ID: 16858944
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
7. [Bone density after iatrogenic subclinical long-term thyrotoxicosis. Measurement by dual photon absorptiometry].
Chabert-Orsini V; Conte-Devolx B; Thiers-Bautrant D; Atlan-Gepner C; Denizot A; Audiffret J; Henry JF; Codaccioni JL
Presse Med; 1990 Nov; 19(37):1709-11. PubMed ID: 2147486
[TBL] [Abstract][Full Text] [Related]
8. [Bone density in differentiated cancer of the thyroid gland treated by hormone-suppressive therapy. Study based on 51 cases].
Eulry F; Bauduceau B; Lechevalier D; Magnin J; Crozes P; Flageat J; Gautier D
Rev Rhum Mal Osteoartic; 1992 Apr; 59(4):247-52. PubMed ID: 1496271
[TBL] [Abstract][Full Text] [Related]
9. [Bone tissue mineral density in patients with thyroid gland cancer on levothyroxine natrium therapy].
Khmara IM; Tolkachev IuV
Klin Med (Mosk); 2005; 83(10):61-5. PubMed ID: 16320850
[TBL] [Abstract][Full Text] [Related]
10. [Discrepancy between the basal level of TSH and the thyrotropic response to TRH during thyroid hormone treatment of differentiated thyroid cancers].
Charrie A; Tourniaire J; Bernard MH; Dutey P; Andrianasolo H; Fleury-Goyon MC
Ann Endocrinol (Paris); 1989; 50(1):31-5. PubMed ID: 2499241
[TBL] [Abstract][Full Text] [Related]
11. [Principles and modalities of hormonal treatment in therapeutic management of differentiated thyroid cancers].
Wemeau JL
Ann Endocrinol (Paris); 1997; 58(3):204-10. PubMed ID: 9239242
[TBL] [Abstract][Full Text] [Related]
12. Effects of suppressive doses of levothyroxine treatment on sex-hormone-binding globulin and bone metabolism.
Lecomte P; Lecureuil N; Osorio-Salazar C; Lecureuil M; Valat C
Thyroid; 1995 Feb; 5(1):19-23. PubMed ID: 7787428
[TBL] [Abstract][Full Text] [Related]
13. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
Ongphiphadhanakul B; Puavilai G; Rajatanavin R
J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
[TBL] [Abstract][Full Text] [Related]
14. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy.
Mazokopakis EE; Starakis IK; Papadomanolaki MG; Batistakis AG; Papadakis JA
Curr Med Res Opin; 2006 Jul; 22(7):1369-73. PubMed ID: 16834835
[TBL] [Abstract][Full Text] [Related]
15. [The risk factors and bone mineral density in women on long-term levothyroxine treatment].
López Alvarez MB; Hawkins F; Rigopoulou D; Martínez G; Jodar E; Estenoz J; Ortuño B; Arnaiz F
Med Clin (Barc); 1999 Jan; 112(3):85-9. PubMed ID: 10074614
[TBL] [Abstract][Full Text] [Related]
16. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma.
Heemstra KA; Hamdy NA; Romijn JA; Smit JW
Thyroid; 2006 Jun; 16(6):583-91. PubMed ID: 16839260
[TBL] [Abstract][Full Text] [Related]
17. [The effect of thyroid hormone on thyroid cancer growth].
Shiba E; Takai S
Gan To Kagaku Ryoho; 1993 Dec; 20(15):2282-8. PubMed ID: 8259840
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral density in patients with chronic hypoparathyroidism.
Abugassa S; Nordenström J; Eriksson S; Sjödén G
J Clin Endocrinol Metab; 1993 Jun; 76(6):1617-21. PubMed ID: 8501170
[TBL] [Abstract][Full Text] [Related]
19. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.
Pacini F; Molinaro E; Lippi F; Castagna MG; Agate L; Ceccarelli C; Taddei D; Elisei R; Capezzone M; Pinchera A
J Clin Endocrinol Metab; 2001 Dec; 86(12):5686-90. PubMed ID: 11739420
[TBL] [Abstract][Full Text] [Related]
20. Thyroid hormone use and bone mineral density in elderly men.
Schneider DL; Barrett-Connor EL; Morton DJ
Arch Intern Med; 1995 Oct; 155(18):2005-7. PubMed ID: 7575055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
